Answers are grounded in this paper and cite their sources.
Updating SARS-CoV-2 vaccines has become a recommendation to enhance immunity induced by vaccination or prior infection, given the continued circulation of variants/subvariants of concern. The waning effectiveness of vaccines and the immune evasion of circulating variants/subvariants require continuous improvements to new vaccine compositions based on multiple platforms. We developed and evaluated monovalent vaccines based on a plasmid DNA platform (pCTV), encoding the Spike protein of the SARS-CoV-2 Wuhan strain (pCTV-Wuhan), the Omicron variant (pCTV-Omicron), and the XBB.1.5 subvariant (pCTV-XBB). Immunogenicity and protective efficacy against the Omicron variant, as well as the XBB.1.5 and JN.1 subvariants, were evaluated in preclinical models using K18-hACE2 mice and Syrian hamsters. Immunizing mice with pCTV-Wuhan and pCTV-Omicron using homologous and heterologous prime-boost schedules showed that only the homologous pCTV-Omicron protocol induced significantly higher neutralizing antibody titers, along with reduced viral RNA levels in the lungs and nasal wash after Omicron variant challenge. Based on these findings and the subsequent emergence of XBB-derived subvariants, we developed a DNA vaccine encoding the XBB.1.5 Spike protein. Immunization with pCTV-XBB elicited robust immune responses, including high antibodies levels and neutralizing activity against XBB.1.5. After XBB.1.5 challenge, vaccinated animals showed reduced viral RNA in the lungs, milder inflammation, improved lung pathology, and protection against disease in both mice and hamsters. Immunization with pCTV-XBB also elicited a cellular immune response, resulting in significant IFN-γ production by CD4 + and CD8 + T cells. However, B-cell-deficient K18-hACE2 (K18-hACE/BKO) mice, immunized with pCTV-XBB and subsequently challenged with XBB.1.5, succumbed to the infection, demonstrating that the protective mechanism relies primarily on the humoral response. T-cell depletion reduced protection in animals infected with the XBB.1.5 subvariant, suggesting that the cellular response also contributes to protective immunity. The pCTV-XBB vaccine also demonstrated cross-protection against the JN.1 subvariant, as evidenced by a significant reduction in viral RNA, particularly in the lungs of challenged animals. Overall, pCTV-XBB conferred protection against the XBB.1.5 and JN.1 subvariants, mediated primarily by a humoral and T-cell response, respectively. These results support continued evaluation of updated DNA vaccines to address the ongoing evolution of SARS-CoV-2.
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: